Daniel Devine & Co decreased its position in Astrazeneca PLC (NYSE:AZN) by 12.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 37,400 shares of the company’s stock after selling 5,300 shares during the period. Astrazeneca PLC comprises approximately 1.0% of Daniel Devine & Co’s holdings, making the stock its 23rd largest position. Daniel Devine & Co’s holdings in Astrazeneca PLC were worth $1,275,000 as of its most recent filing with the SEC.
Several other institutional investors also recently made changes to their positions in AZN. Capstone Asset Management Co. increased its position in shares of Astrazeneca PLC by 6.9% in the first quarter. Capstone Asset Management Co. now owns 103,471 shares of the company’s stock worth $3,222,000 after buying an additional 6,660 shares in the last quarter. LVM Capital Management Ltd. MI increased its position in shares of Astrazeneca PLC by 11.4% in the first quarter. LVM Capital Management Ltd. MI now owns 9,800 shares of the company’s stock worth $305,000 after buying an additional 1,000 shares in the last quarter. Quadrant Capital Group LLC increased its position in shares of Astrazeneca PLC by 157.1% in the first quarter. Quadrant Capital Group LLC now owns 4,591 shares of the company’s stock worth $138,000 after buying an additional 2,805 shares during the period. Creative Planning increased its position in shares of Astrazeneca PLC by 9.8% in the first quarter. Creative Planning now owns 45,321 shares of the company’s stock worth $1,411,000 after buying an additional 4,040 shares during the period. Finally, Raymond James Trust N.A. increased its position in shares of Astrazeneca PLC by 36.2% in the first quarter. Raymond James Trust N.A. now owns 53,434 shares of the company’s stock worth $1,664,000 after buying an additional 14,216 shares during the period. 14.33% of the stock is owned by institutional investors and hedge funds.
Astrazeneca PLC (NYSE:AZN) opened at 29.75 on Wednesday. Astrazeneca PLC has a 52-week low of $25.55 and a 52-week high of $35.60. The stock has a market capitalization of $75.33 billion, a P/E ratio of 19.51 and a beta of 0.74. The company’s 50-day moving average price is $33.23 and its 200 day moving average price is $31.34.
Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.87 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.46. The business had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The firm’s revenue was down 9.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.83 EPS. On average, equities research analysts anticipate that Astrazeneca PLC will post $1.85 earnings per share for the current year.
The firm also recently disclosed a None dividend, which will be paid on Monday, September 11th. Investors of record on Friday, August 11th will be paid a dividend of $0.44 per share. This represents a yield of 2.98%. The ex-dividend date of this dividend is Wednesday, August 9th. Astrazeneca PLC’s payout ratio is presently 44.92%.
ILLEGAL ACTIVITY WARNING: “Daniel Devine & Co Lowers Stake in Astrazeneca PLC (AZN)” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://stocknewstimes.com/2017/08/09/daniel-devine-co-has-1-28-million-stake-in-astrazeneca-plc-azn-updated-updated.html.
A number of brokerages recently issued reports on AZN. BidaskClub downgraded Astrazeneca PLC from a “sell” rating to a “strong sell” rating in a report on Friday, August 4th. Barclays PLC reiterated an “overweight” rating on shares of Astrazeneca PLC in a research note on Thursday, July 13th. Morgan Stanley cut Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a research note on Friday, July 28th. Pareto Securities upgraded Astrazeneca PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Finally, Goldman Sachs Group, Inc. (The) reiterated a “sell” rating on shares of Astrazeneca PLC in a research note on Thursday, July 13th. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $33.39.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.
